New version of Merck’s cancer drug faces possible patent battle: reports

Halozyme Therapeutics claims Merck’s new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ Health Halozyme Therapeutics claims Merck’s new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ Sci-Tech News | Latest Technological Developments | The Hindu